Can-Fite BioPharma Ltd. (CANF) |
|
3.68 -0.19 (-4.91%)
|
12-06 16:00 |
|
Open: |
3.84 |
Pre. Close: |
3.87 |
|
High:
|
3.8449 |
Low:
|
3.45 |
|
Volume:
|
217,898 |
Market Cap:
|
16M |
|
|
|
|
Can Fite Biofarma Ltd is a clinical stage biopharmaceutical company. It develops orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.845 - 3.869 |
3.869 - 3.886 |
|
Low:
|
3.397 - 3.425 |
3.425 - 3.445 |
|
Close:
|
3.642 - 3.684 |
3.684 - 3.715 |
|
Technical analysis |
as of: 2019-12-06 4:33:13 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 5.78 One year: 6.75 |
| Support: |
Support1: 3.24 Support2: 2.18 |
| Resistance: |
Resistance1: 4.95 Resistance2: 5.78 |
| Pivot: |
3.06  |
| Moving Average: |
MA(5): 3.98 MA(20): 2.90
MA(100): 2.54 MA(250): 7.80 |
| MACD: |
MACD(12,26): 0.42 Signal(9): 0.28 |
| Stochastic oscillator: |
%K(14,3): 63.62 %D(3): 65.84 |
| RSI: |
RSI(14): 61.31 |
| 52-week: |
High: 24.30 Low: 1.90 Change(%): -80.8 |
| Average Vol(K): |
3-Month: 44340 10-Days: 140481 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.CANF has closed below upper band by 28.6%. Bollinger Bands are 312.4% wider than normal. The large width of the bands suggest high volatility as compared to CANF's normal range. The bands have been in this wide range for 5 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
2019-11-21
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on November 25, 2019
PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its CEO Pnina Fishman Ph.D. will share insight into the Company’s recent developments during an investor webinar on Monday, November 25, 2019 at 11:00 a.m. ET. A live Q&A session with Dr. Fishman will follow her presentation. To join the Can-Fite webinar, please
2019-11-11
Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals
Israeli biotechnology company Can-Fite BioPharma Ltd . (NYSE: CANF ) said Monday that its drug candidate Piclidenoson for the treatment of osteoarthritis in mammals has been granted Patent No. 10,265,337 from the U.S. Patent and Trademark Office with the title “Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment.” The company is considering possible partnerships with companies from the animal health pharmaceutical industry that could in-license and create Piclidenoson for the companion animal market. Canine osteoarthritis is being treated with oral non-steroidal anti-inflammatory drugs that only address symptoms and have damaging side effects, and an injectable disease modifying osteoarthritis drug which only affects the progression of … Full story available on Benzinga.com
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
